Clinical Trial Update: Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating long-term safety of safinamide in Parkinson's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Newron Pharmaceuticals SPA | Conditions: Parkinson's Disease | Phase 3 | Status: TERMINATED